RecruitingExpanded accessNCT03601442 ↗Managed Access Programs for CTL019, TisagenlecleucelGaurav Varma
RecruitingExpanded accessNCT04400591 ↗Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial ReleaseGaurav VarmaPIInterventionBiological: Nonconforming Lisocabtagene MaraleucelDatesStarted Nov 2021SponsorJuno Therapeutics, Inc.Lymphoma, Large B-Cell, Diffuse
RecruitingExpanded accessNCT04771078 ↗Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial ReleaseRoger N PearsePIInterventionBiological: Nonconforming idecabtagene vicleucelDatesStarted Sep 2021SponsorCelgene CorporationMultiple Myeloma
RecruitingExpanded accessNCT05346835 ↗Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple MyelomaRuben NiesvizkyPIInterventionDrug: Cilta-cel OOS TherapyDatesStarted Jul 2022SponsorJanssen Scientific Affairs, LLCMultiple Myeloma
RecruitingExpanded accessNCT05398640 ↗Expanded Access Program of AMTAGVI That is Out of Specification for Commercial ReleaseBarbara MaPIInterventionBiological: OOS AMTAGVIDatesStarted Nov 2025SponsorIovance Biotherapeutics, IncUnresectable MelanomaMetastatic Melanoma
RecruitingExpanded accessNCT05776134 ↗Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelGaurav VarmaPIInterventionBiological: Brexucabtagene AutoleucelDatesStarted Aug 2024SponsorKite Pharma, Inc.Mantle Cell LymphomaAcute Lymphoblastic Leukemia
RecruitingExpanded accessNCT05776160 ↗Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelGaurav VarmaPIInterventionDrug: Axicabtagene CiloleucelDatesStarted Aug 2024SponsorKite Pharma, Inc.Large B-cell LymphomaFollicular Lymphoma
RecruitingExpanded accessNCT06780579 ↗Expanded Access Treatment Protocol for BulevirtideTatyana KushnerPIInterventionDrug: BulevirtideDatesStarted Sep 2025SponsorGilead Sciences, Inc.Chronic Hepatitis Delta Virus Infection
RecruitingExpanded accessNCT06799221 ↗Expanded Access Program (EAP) for Obecabtagene Autoleucel (Obe-cel) Out-of-specification (OOS) in Adult Patients With Acute Lymphoblastic LeukemiaGaurav VarmaPIInterventionBiological: Out-of-specification obecabtagene autoleucelDatesStarted Jun 2026SponsorAutolus INCLymphoblastic Leukemia, Acute, AdultB Cell ALL
RecruitingExpanded accessNCT06994117 ↗Expanded Access for MezigdomideRuben NiesvizkyPIInterventionDrug: MezigdomideDatesStarted Jul 2026SponsorBristol-Myers Squibb Company
CompletedExpanded accessNCT03763370 ↗Managed Access Program for Belantamab Mafodotin in Combination With Either Bortezomib/Dexamethasone or Pomalidomide/Dexamethasone in Patients With Multiple Myeloma Previously Treated With at Least 1 Prior Line of TherapyRuben NiesvizkyPIInterventionDrug: Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd) · Drug: Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)DatesStarted Jun 2020SponsorGlaxoSmithKlineMultiple Myeloma
CompletedExpanded accessNCT04323761 ↗Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) InfectionHarjot Kaur SinghPIInterventionDrug: RemdesivirDatesStarted Apr 2020SponsorGilead Sciences, Inc.SARS-CoV2 Infection
CompletedExpanded accessNCT04334070 ↗Novartis Multiple Patient Program for Lamprene® (Clofazimine) for the Treatment of Non-Tuberculous Mycobacterial (NTM) InfectionsOle VielemeyerPIInterventionDrug: Lamprene®/ClofazimineDatesStarted Mar 2024SponsorNovartis Pharmaceuticals CorporationNon-Tuberculous Mycobacterial (NTM) Infections
CompletedExpanded accessNCT04360005 ↗Managed Access Programs for ABL001, AsciminibGail J RobozPIInterventionDrug: AsciminibDatesStarted Jun 2021SponsorWeill Medical College of Cornell UniversityChronic Myeloid Leukemia in Chronic Phase
CompletedExpanded accessNCT05462639 ↗ELRANATAMAB (PF-06863135) MONOTHERAPY EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPYRuben NiesvizkyPIInterventionDrug: Elranatamab (PF-06863135)DatesStarted Dec 2022SponsorPfizer, Inc.Multiple Myeloma
CompletedExpanded accessNCT05544032 ↗Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)Tsiporah B ShorePIInterventionDrug: axatilimabDatesStarted May 2024SponsorIncyte CorporationChronic Graft Vs. Host Disease
CompletedExpanded accessNCT05757973 ↗64407564MMY4003: 64407564MMY4003 - Talquetamab NPP GlobalRuben NiesvizkyPIInterventionDrug: TalquetamabDatesStarted Jul 2023SponsorJanssen Research & Development, LLCRelapsed or Refractory Multiple Myeloma
CompletedExpanded accessNCT06321705 ↗Expanded Access, Open-Label, Safety Extension Study for Patients That Have Completed Parent Study CS1-003 and Who Are Judged by the Investigator to Benefit From Continued CS1 TreatmentEvelyn M. HornPIInterventionDrug: CS1DatesStarted Nov 2024SponsorCereno Scientific ABPulmonary Arterial Hypertension
CompletedExpanded accessNCT06796426 ↗A Treatment Protocol for the Use of Plozasiran in Adults With Familial Chylomicronemia Syndrome (FCS). A Single Patient Protocol for the Use of Plozasiran In Adolescents With Familial Chylomicronemia Syndrome (FCS). An Expanded Access Treatment Protocol for Use of Plozasiran In Adults With High-Risk Severe Hypertriglyceridemia (SHTG).Samuel KimPIInterventionDrug: PlozasiranDatesStarted Mar 2025SponsorArrowhead Pharmaceuticals INCFamilial ChylomicronemiaHigh Risk Severe Hypertriglyceridemia (SHTG)